| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2022-03-07 02:49:06 UTC |
|---|
| HMDB ID | HMDB0000746 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Hydroxyisocaproic acid |
|---|
| Description | Hydroxyisocaproic acid is an end product of leucine metabolism in human tissues such as muscle and connective tissue. It belongs to 2-hydroxycarboxylic acid group of amino acid metabolites (PMID 6434570 ). Hydroxyisocaproic acid functions as an “anti-catabolite” and is widely used in the body building community. Chronic alpha-hydroxyisocaproic acid treatment of rats has been shown to improve muscle recovery after immobilization-induced atrophy (PMID: 23757407 ). Additionally, a 4-week hydroxyisocaproic acid supplementation of 1.5 g a day was shown to lead to increases in muscle mass during an intensive training period among soccer athletes (PMID: 20051111 ). Hydroxyisocaproic acid has also shown some potential as a topical antibiotic (PMID: 22483561 ). Elevated levels of 2-hydroxyisocaproic acid have been found in the urine of patients with dihydrolipoyl dehydrogenase (E3) deficiency (PMID: 6688766 ). Hydroxyisocaproic acid is also elevated in maple syrup urine disease, a genetic disorder, and has been shown to accelerate lipid peroxidation. It may also be an indicator of oxidative stress (PMID: 11894849 ). Hydroxyisocaproic acid has been found to be a metabolite of Lactobacillus and fungal species (http://jultika.oulu.fi/files/isbn9789526211046.pdf). |
|---|
| Structure | InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/t5-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-2-Hydroxyisocaproic acid | ChEBI | | (+)-alpha-Hydroxyisocaproic acid | ChEBI | | (S)-2-Hydroxyisocaproic acid | ChEBI | | (S)-Leucic acid | ChEBI | | 2-HYDROXY-4-methyl-pentanoIC ACID | ChEBI | | L-2-Hydroxy-4-methylvaleric acid | ChEBI | | L-2-Hydroxyisocaproic acid | ChEBI | | L-alpha-Hydroxyisocaproic acid | ChEBI | | L-Leucic acid | ChEBI | | (+)-2-Hydroxyisocaproate | Generator | | (+)-a-Hydroxyisocaproate | Generator | | (+)-a-Hydroxyisocaproic acid | Generator | | (+)-alpha-Hydroxyisocaproate | Generator | | (+)-Α-hydroxyisocaproate | Generator | | (+)-Α-hydroxyisocaproic acid | Generator | | (S)-2-Hydroxyisocaproate | Generator | | (S)-Leucate | Generator | | 2-HYDROXY-4-methyl-pentanoate | Generator | | L-2-Hydroxy-4-methylvalerate | Generator | | L-2-Hydroxyisocaproate | Generator | | L-a-Hydroxyisocaproate | Generator | | L-a-Hydroxyisocaproic acid | Generator | | L-alpha-Hydroxyisocaproate | Generator | | L-Α-hydroxyisocaproate | Generator | | L-Α-hydroxyisocaproic acid | Generator | | L-Leucate | Generator | | Hydroxyisocaproate | Generator | | Hydroxy-isocaproate | HMDB | | (2S)-2-Hydroxy-4-methylpentanoate | HMDB | | (2S)-2-Hydroxy-4-methylpentanoic acid | HMDB | | (S)-2-Hydroxy-4-methyl-pentanoate | HMDB | | (S)-2-Hydroxy-4-methyl-pentanoic acid | HMDB | | S-2-Hydroxy-4-methylpentanoate | HMDB | | S-2-Hydroxy-4-methylpentanoic acid | HMDB |
|
|---|
| Chemical Formula | C6H12O3 |
|---|
| Average Molecular Weight | 132.1577 |
|---|
| Monoisotopic Molecular Weight | 132.07864425 |
|---|
| IUPAC Name | (2S)-2-hydroxy-4-methylpentanoic acid |
|---|
| Traditional Name | (+)-α-hydroxyisocaproate |
|---|
| CAS Registry Number | 13748-90-8 |
|---|
| SMILES | CC(C)C[C@H](O)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/t5-/m0/s1 |
|---|
| InChI Key | LVRFTAZAXQPQHI-YFKPBYRVSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as hydroxy fatty acids. These are fatty acids in which the chain bears a hydroxyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Fatty acids and conjugates |
|---|
| Direct Parent | Hydroxy fatty acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Branched fatty acid
- Hydroxy fatty acid
- Methyl-branched fatty acid
- Alpha-hydroxy acid
- Hydroxy acid
- Secondary alcohol
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organooxygen compound
- Carbonyl group
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | |
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.07 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.003 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.24 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 61.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1362.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 360.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 100.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 213.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 82.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 401.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 420.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 98.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 768.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 330.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1122.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 248.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 306.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 420.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 281.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 131.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Hydroxyisocaproic acid,1TMS,isomer #1 | CC(C)C[C@H](O[Si](C)(C)C)C(=O)O | 1189.3 | Semi standard non polar | 33892256 | | Hydroxyisocaproic acid,1TMS,isomer #2 | CC(C)C[C@H](O)C(=O)O[Si](C)(C)C | 1121.8 | Semi standard non polar | 33892256 | | Hydroxyisocaproic acid,2TMS,isomer #1 | CC(C)C[C@H](O[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1237.3 | Semi standard non polar | 33892256 | | Hydroxyisocaproic acid,1TBDMS,isomer #1 | CC(C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=O)O | 1404.6 | Semi standard non polar | 33892256 | | Hydroxyisocaproic acid,1TBDMS,isomer #2 | CC(C)C[C@H](O)C(=O)O[Si](C)(C)C(C)(C)C | 1356.0 | Semi standard non polar | 33892256 | | Hydroxyisocaproic acid,2TBDMS,isomer #1 | CC(C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 1676.3 | Semi standard non polar | 33892256 |
|
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9000000000-866999574fff80fabad1 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (2 TMS) - 70eV, Positive | splash10-02gc-9440000000-7fffd162011678b17f4a | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Hydroxyisocaproic acid GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Hydroxyisocaproic acid Quattro_QQQ 10V, Negative-QTOF (Annotated) | splash10-001r-7900000000-716c5f55d60f6894323b | 2012-07-24 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Hydroxyisocaproic acid Quattro_QQQ 25V, Negative-QTOF (Annotated) | splash10-014s-9000000000-9c50133cdf095ca16a2e | 2012-07-24 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Hydroxyisocaproic acid Quattro_QQQ 40V, Negative-QTOF (Annotated) | splash10-00kb-9100000000-dc2c3e9343c9a8e307c3 | 2012-07-24 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 10V, Positive-QTOF | splash10-0159-5900000000-01e9c211c49cea6fc5c6 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 20V, Positive-QTOF | splash10-0ap0-9300000000-a1f6fc289aa530d63fd8 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 40V, Positive-QTOF | splash10-0a4i-9000000000-eb5a5d102c8e756f6834 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 10V, Negative-QTOF | splash10-001i-2900000000-1a66b9767516fbd45630 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 20V, Negative-QTOF | splash10-06s9-9400000000-cf71f1c20e2a87bbb2b0 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 40V, Negative-QTOF | splash10-0a4i-9000000000-11e049c8df5b1a6268c9 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 10V, Negative-QTOF | splash10-0019-9700000000-a7d0b1ce1c211b31bc0d | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 20V, Negative-QTOF | splash10-00kr-9100000000-504826b66e199a65ef09 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 40V, Negative-QTOF | splash10-014l-9000000000-ccecb4a470c359949fec | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 10V, Positive-QTOF | splash10-014i-9000000000-3019a9d0620e7da01963 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 20V, Positive-QTOF | splash10-00kf-9000000000-e587d44396e53f2409fa | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hydroxyisocaproic acid 40V, Positive-QTOF | splash10-0006-9000000000-457ece1d510dad645c89 | 2021-09-24 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | |
|---|
| Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Urine
|
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected and Quantified | <0.7 uM | Newborn (0-30 days old) | Not Specified | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | <0.7 uM | Newborn (0-30 days old) | Not Specified | Normal | | details | | Saliva | Detected and Quantified | 6.17 +/- 7.65 uM | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 14 uM | Newborn (0-30 days old) | Female | Maple syrup urine disease | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 12.9 uM | Newborn (0-30 days old) | Female | Maple syrup urine disease | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Supragingival Plaque | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Tooth Decay | | details | | Urine | Detected and Quantified | 41.5 (3.00-80.00) umol/mmol creatinine | Children (1-13 years old) | Both | Maple syrup urine disease (MSUD) | | details | | Urine | Detected and Quantified | 1.855 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
| | Supragingival Plaque |
|---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| | Tooth Decay |
|---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| | Maple syrup urine disease |
|---|
- Shigematsu Y, Kikuchi K, Momoi T, Sudo M, Kikawa Y, Nosaka K, Kuriyama M, Haruki S, Sanada K, Hamano N, et al.: Organic acids and branched-chain amino acids in body fluids before and after multiple exchange transfusions in maple syrup urine disease. J Inherit Metab Dis. 1983;6(4):183-9. [PubMed:6422161 ]
- G.Frauendienst-Egger, Friedrich K. Trefz (2017). MetaGene: Metabolic & Genetic Information Center (MIC: http://www.metagene.de). METAGENE consortium.
| | Eosinophilic esophagitis |
|---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
|---|
| Associated OMIM IDs | - 114500 (Colorectal cancer)
- 248600 (Maple syrup urine disease)
- 610247 (Eosinophilic esophagitis)
|
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB022218 |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 75520 |
|---|
| KEGG Compound ID | Not Available |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | 2-Hydroxyisocaproic acid |
|---|
| METLIN ID | 5714 |
|---|
| PubChem Compound | 83697 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 44510 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | MDB00000243 |
|---|
| Good Scents ID | rw1136521 |
|---|
| References |
|---|
| Synthesis Reference | Schmidt, E. G.; Peterson, W. H.; Fred, E. B. The formation of l-leucic acid in the acetone-butyl alcohol fermentation. Journal of Biological Chemistry (1924), 61 163-75. |
|---|
| Material Safety Data Sheet (MSDS) | Download (PDF) |
|---|
| General References | - Kuhara T, Shinka T, Inoue Y, Matsumoto M, Yoshino M, Sakaguchi Y, Matsumoto I: Studies of urinary organic acid profiles of a patient with dihydrolipoyl dehydrogenase deficiency. Clin Chim Acta. 1983 Sep 30;133(2):133-40. [PubMed:6688766 ]
- Liebich HM, Forst C: Hydroxycarboxylic and oxocarboxylic acids in urine: products from branched-chain amino acid degradation and from ketogenesis. J Chromatogr. 1984 Aug 10;309(2):225-42. [PubMed:6434570 ]
- Fontella FU, Gassen E, Pulrolnik V, Wannmacher CM, Klein AB, Wajner M, Dutra-Filho CS: Stimulation of lipid peroxidation in vitro in rat brain by the metabolites accumulating in maple syrup urine disease. Metab Brain Dis. 2002 Mar;17(1):47-54. [PubMed:11894849 ]
- Lang CH, Pruznak A, Navaratnarajah M, Rankine KA, Deiter G, Magne H, Offord EA, Breuille D: Chronic alpha-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. Am J Physiol Endocrinol Metab. 2013 Aug 1;305(3):E416-28. doi: 10.1152/ajpendo.00618.2012. Epub 2013 Jun 11. [PubMed:23757407 ]
- Mero AA, Ojala T, Hulmi JJ, Puurtinen R, Karila TA, Seppala T: Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. J Int Soc Sports Nutr. 2010 Jan 5;7:1. doi: 10.1186/1550-2783-7-1. [PubMed:20051111 ]
- Sakko M, Tjaderhane L, Sorsa T, Hietala P, Jarvinen A, Bowyer P, Rautemaa R: 2-Hydroxyisocaproic acid (HICA): a new potential topical antibacterial agent. Int J Antimicrob Agents. 2012 Jun;39(6):539-40. doi: 10.1016/j.ijantimicag.2012.02.006. Epub 2012 Apr 5. [PubMed:22483561 ]
|
|---|